Ideaya Biosciences Inc (IDYA) - Total Liabilities
Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) has total liabilities worth $93.10 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Ideaya Biosciences Inc to assess how effectively this company generates cash.
Ideaya Biosciences Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Ideaya Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check IDYA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Ideaya Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Ideaya Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuxi Nce Power Co Ltd
SHG:605111
|
China | CN¥438.07 Million |
|
Woolworths Holdings Ltd
JSE:WHL
|
South Africa | ZAC30.14 Billion |
|
Qingdao Rural Commercial Bank Corp Class A
SHE:002958
|
China | CN¥472.75 Billion |
|
Zhejiang Publishing & Media Co Ltd
SHG:601921
|
China | CN¥8.17 Billion |
|
Data Patterns (India) Limited
NSE:DATAPATTNS
|
India | Rs2.15 Billion |
|
Bel Fuse B Inc
NASDAQ:BELFB
|
USA | $416.53 Million |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs5.37 Billion |
|
ABM Industries Incorporated
NYSE:ABM
|
USA | $3.67 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Ideaya Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ideaya Biosciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ideaya Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ideaya Biosciences Inc (2017–2024)
The table below shows the annual total liabilities of Ideaya Biosciences Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $64.94 Million | +130.09% |
| 2023-12-31 | $28.23 Million | -26.71% |
| 2022-12-31 | $38.51 Million | -51.76% |
| 2021-12-31 | $79.83 Million | -20.16% |
| 2020-12-31 | $100.00 Million | +693.55% |
| 2019-12-31 | $12.60 Million | -91.34% |
| 2018-12-31 | $145.49 Million | +337.98% |
| 2017-12-31 | $33.22 Million | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methion… Read more